Last checked at 30 Dec 2021 07:00
Ovoca Bio plc
("Ovoca" or the "Company")
Directorate Change
Ovoca Bio plc (LSE: OVB; ISE: OVXA) announces that Dr. Romulo Colindres has informed the Board of his decision to step down as a Non-Executive Director of the Company, with immediate effect, for both personal and business reasons. Dr. Colindres stated: "It has been a pleasure to be involved with the Ovoca board and team and wish them much success along the path to making orenetide available to patients".
Kirill Golovanov, CEO of Ovoca, commented: "On behalf of the Company, I would like to thank Romulo for his contribution to the board of Ovoca. We wish Romulo well in his future endeavours."
End
For further information:
Ovoca Bio plc
Kirill Golovanov (Chief Executive)
Tel +353 1 661 9819
info@ovocabio.com
Davy (Nominated Adviser, Euronext Growth Advisor and Broker)
John Frain / Daragh O'Reilly
Tel: +353 1 679 6363
Consilium Strategic Communications
Chris Gardner, Chris Welsh, Carina Jurs
ovocabio@consilium-comms.com
Tel: +44 (0)20 3709 5700
About Ovoca Bio
Ovoca Bio is a European-based biopharmaceutical company with a focus on women's health. The Company is currently developing a novel treatment for women with hypoactive sexual desire disorder (HSDD).
The Company's lead product, BP-101, a novel synthetic peptide administered through a nasal spray, is clinically validated, with Phase II and Phase III studies conducted in Russia demonstrating statistically significant improvement in a number of key efficacy outcomes, including an increase in female sexual desire and reduction of symptoms of distress associated with HSDD.
Ovoca Bio is seeking to develop the drug for major global markets - in particular the United States and Europe, as well as obtain marketing approval in the Russian Federation.